The discovery of regulatory T cells (Tregs) was honored with the 2025 Nobel Prize in Medicine, underscoring their central role in immune suppression. In this webinar, we will explore one of the most promising directions in immuno-oncology: CCR8⁺ Tregs. With Domain Therapeutics, a clinical-stage biopharmaceutical company advancing novel GPCR-targeting therapies, and Explicyte, a CRO specialized in translational research and tumor microenvironment analysis, we’ll connect drug design to patient-anchored evidence in solid tumors—showing how CCR8 can serve as both a therapeutic target and a predictive biomarker.
October 28, 2025 I 4 PM CET I 11 AM EDT
Anti-CCR8 Antibodies: From Treg Depletion to Immune Reawakening
Dr. Schann will present Domain’s novel differentiated strategy for selective Treg depletion and introduce DT-7012, its clinical Treg-depleting anti-CCR8 antibody candidate. He will outline the clinical rationale for targeting CCR8 in solid tumors, highlight DT-7012’s differentiation from other anti-CCR8 antibodies currently in the clinic, and show how this best-in-class candidate is engineered to overcome immune resistance and deliver durable responses—even in CCL1-rich tumors and anti-PD-1-refractory settings.
CCR8⁺ Tregs and Their Correlation with Immunotherapy Response in Advanced NSCLC
Dr. Bessède will present a collaborative study between Explicyte, Institut Bergonié, Gustave Roussy, and Bayer, analyzing an NSCLC cohort (BIP, NCT02534649) treated with standard-of-care immune checkpoint inhibitors. Using a validated 6-plex IHF panel, CCR8⁺ Tregs were quantified in pretreatment tumor samples and correlated with clinical outcomes (PFS, ORR), immune contexture (inflamed/infiltrated, excluded, or desert), PD-L1 TPS, and TLS status. The analysis highlights the differential predictive impact of CCR8⁺ Tregs in NSCLC, with a specific negative influence in TLS-positive tumors.
📥 Bonus: Download our free landscape of anti-CCR8 therapeutics in development
Targeting Tregs in Solid Tumors: Anti-CCR8 Therapeutics & Translational Insights (45-min webinar)
October 28, 2025 I 4 PM CET I 11 AM EDT
Anti-CCR8 Antibodies: From Treg Depletion to Immune Reawakening
Stephan Schann, PhD – CSO, Domain Therapeutics
Dr. Schann will present Domain’s novel differentiated strategy for selective Treg depletion and introduce DT-7012, its clinical Treg-depleting anti-CCR8 antibody candidate. He will outline the clinical rationale for targeting CCR8 in solid tumors, highlight DT-7012’s differentiation from other anti-CCR8 antibodies currently in the clinic, and show how this best-in-class candidate is engineered to overcome immune resistance and deliver durable responses—even in CCL1-rich tumors and anti-PD-1-refractory settings.
CCR8⁺ Tregs and Their Correlation with Immunotherapy Response in Advanced NSCLC
Alban Bessède, PhD – CEO, Explicyte
Dr. Bessède will present a collaborative study between Explicyte, Institut Bergonié, Gustave Roussy, and Bayer, analyzing an NSCLC cohort (BIP, NCT02534649) treated with standard-of-care immune checkpoint inhibitors. Using a validated 6-plex IHF panel, CCR8⁺ Tregs were quantified in pretreatment tumor samples and correlated with clinical outcomes (PFS, ORR), immune contexture (inflamed/infiltrated, excluded, or desert), PD-L1 TPS, and TLS status. The analysis highlights the differential predictive impact of CCR8⁺ Tregs in NSCLC, with a specific negative influence in TLS-positive tumors.
👉 Register now
📥 Bonus: Download our free landscape of anti-CCR8 therapeutics in development
